This article was published on April 1, 2023, at NEJM.org. List of authors. On January 6, 2023, the Food and Drug Administration (FDA) granted accelerated approval to lecanemab (Leqembi), a monoclonal antibody for treating Alzheimer’s disease that targets βamyloid. New drug approvals for diseases causing substantial morbidity and mortality are typically lauded by patients, clinicians,… Continue reading Ensuring Public Trust in an Empowered FDA
Using information provided by the Food and Drug Administration, on the FDA’s website: Unless otherwise noted, the contents of the FDA website (www.fda.gov) — both text and graphics — are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission… Continue reading Linking to or Copying Information on the FDA Website
Researchers are excited about the AI — but many are frustrated that its underlying engineering is cloaked in secrecy The GPT-4 artificial-intelligence model is not yet widely available. Credit: Jaap Arriens/NurPhotovia Getty Images Artificial intelligence company OpenAI this week unveiled GPT-4, the latest incarnation of the large language model that powers its popular chat bot… Continue reading GPT-4 is here: what scientists think
